TrialAnnals of oncology : official journal of the European Society for Medical Oncology2017

Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study.

M E Pavel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.